No Data
No Data
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $34
OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Onkure Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $34 From $40
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $31
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects